{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:40:43Z","timestamp":1790862043740,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.leukres.2011.10.022","type":"journal-article","created":{"date-parts":[[2011,12,8]],"date-time":"2011-12-08T23:18:49Z","timestamp":1323386329000},"page":"342-349","source":"Crossref","is-referenced-by-count":44,"title":["Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis"],"prefix":"10.1016","volume":"36","author":[{"given":"Chong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Ku","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor Z.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor P.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min H.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2011.10.022_bib0005","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/j.1460-2075.1995.tb07021.x","article-title":"Glucocorticoid-induced apoptosis of human leukemic cells is caused by the repressive function of the glucocorticoid receptor","volume":"14","author":"Helmberg","year":"1995","journal-title":"EMBO J"},{"key":"10.1016\/j.leukres.2011.10.022_bib0010","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0092-8674(00)81183-6","article-title":"DNA binding of the glucocorticoid receptor is not essential for survival","volume":"93","author":"Reichardt","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2011.10.022_bib0015","doi-asserted-by":"crossref","first-page":"9712","DOI":"10.1158\/0008-5472.CAN-05-1227","article-title":"Loss of heterozygosity and somatic mutations of the glucocorticoid receptor gene are rarely found at relapse in pediatric acute lymphoblastic leukemia but may occur in a subpopulation early in the disease course","volume":"65","author":"Irving","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2011.10.022_bib0020","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","article-title":"The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism","volume":"7","author":"Engelman","year":"2006","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.leukres.2011.10.022_bib0025","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1073\/pnas.96.8.4240","article-title":"New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase\/AKT pathway","volume":"69","author":"Cantley","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.leukres.2011.10.022_bib0030","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1172\/JCI34616","article-title":"PTEN posttranslational inactivation and hyperactivation of the PI3K\/Akt pathway sustain primary T cell leukemia viability","volume":"118","author":"Silva","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.leukres.2011.10.022_bib0035","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Regulation of Akt\/PKB by the Rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.leukres.2011.10.022_bib0040","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1128\/MCB.24.1.200-216.2004","article-title":"mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1\/eukaryotic translation initiation factor 4E","volume":"24","author":"Fingar","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.leukres.2011.10.022_bib0045","doi-asserted-by":"crossref","first-page":"10853","DOI":"10.1073\/pnas.0804821105","article-title":"mTORC1 promotes survival through translational control of Mcl-1","volume":"105","author":"Mills","year":"2008","journal-title":"PNAS"},{"key":"10.1016\/j.leukres.2011.10.022_bib0050","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol Cell"},{"key":"10.1016\/j.leukres.2011.10.022_bib0055","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrc1974","article-title":"mTOR and cancer: insights into a complex relationship","volume":"6","author":"Sabatini","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.leukres.2011.10.022_bib0060","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.10.022_bib0065","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2011.10.022_bib0070","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.exphem.2007.12.008","article-title":"Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma","volume":"36","author":"Yazbeck","year":"2008","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2011.10.022_bib0075","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.10.022_bib0080","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1200\/JCO.2005.66.130","article-title":"Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer","volume":"23","author":"Chan","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.10.022_bib0085","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa042831","article-title":"Sirolimus for Kaposi's sarcoma in renal-transplant recipients","volume":"352","author":"Stallone","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2011.10.022_bib0090","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1200\/JCO.2008.20.0766","article-title":"Targeting the mTOR signaling network for cancer therapy","volume":"27","author":"Meric-Bernstam","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.10.022_bib0095","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nm1042","article-title":"The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis","volume":"10","author":"Ruggero","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.leukres.2011.10.022_bib0100","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nature02369","article-title":"Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy","volume":"428","author":"Wendel","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2011.10.022_bib0105","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1038\/sj.bjc.6605072","article-title":"Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism","volume":"100","author":"Beesley","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.leukres.2011.10.022_bib0110","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ccr.2006.09.006","article-title":"Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance","volume":"10","author":"Wei","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2011.10.022_bib0115","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1038\/leu.2008.204","article-title":"Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis","volume":"22","author":"Gu","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2011.10.022_bib0120","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1182\/blood-2009-02-206722","article-title":"High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia","volume":"114","author":"Gutierrez","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.10.022_bib0125","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nature04703","article-title":"Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells","volume":"441","author":"Yilmaz","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2011.10.022_bib0130","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1158\/1535-7163.MCT-09-0952","article-title":"Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program","volume":"9","author":"Houghton","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.leukres.2011.10.022_bib0135","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0360-3016(91)90057-B","article-title":"Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation","volume":"20","author":"Brown","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.leukres.2011.10.022_bib0140","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1073\/pnas.121616198","article-title":"Short tandem repeat profiling provides an international reference standard for human cell lines","volume":"98","author":"Masters","year":"2001","journal-title":"PNAS"},{"key":"10.1016\/j.leukres.2011.10.022_bib0145","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/jnci\/djn076","article-title":"Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation","volume":"100","author":"Kang","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.leukres.2011.10.022_bib0150","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2141.2005.05881.x","article-title":"Inhibition of the phosphatidylinositol-3 kinase\/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma","volume":"132","author":"Georgakis","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2011.10.022_bib0155","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose\u2013effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"10.1016\/j.leukres.2011.10.022_bib0160","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1200\/JCO.2008.16.2347","article-title":"Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors","volume":"26","author":"Jimeno","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.10.022_bib0165","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2011.10.022_bib0170","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1056\/NEJM197504172921604","article-title":"Clinical importance of lymphoblasts with T markers in childhood acute leukemia","volume":"292","author":"Sen","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2011.10.022_bib0175","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/leu.2009.262","article-title":"Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983\u20132002: a Children's Oncology Group Report","volume":"24","author":"Gaynon","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2011.10.022_bib0180","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/leu.2009.257","article-title":"Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000","volume":"24","author":"Moricke","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2011.10.022_bib0185","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1200\/JCO.2003.10.116","article-title":"Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Experience","volume":"21","author":"Goldberg","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.10.022_bib0190","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/sj.leu.2401129","article-title":"Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia\u2014implications for treatment of infants","volume":"12","author":"Pieters","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2011.10.022_bib0195","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1475-2867-7-3","article-title":"Pathway interactions between MAPKs, mTOR, PKA, and the glucocorticoid receptor in lymphoid cells","volume":"7","author":"Miller","year":"2007","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.leukres.2011.10.022_bib0200","doi-asserted-by":"crossref","first-page":"8423","DOI":"10.1158\/0008-5472.CAN-05-0058","article-title":"Inhibition of the phosphatidylinositol 3-kinase\/Akt\/mammalian target of rapamycin pathway but not the MEK\/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy","volume":"65","author":"Tsurutani","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2011.10.022_bib0205","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1101\/gad.995802","article-title":"Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1\/eIF4E","volume":"16","author":"Fingar","year":"2002","journal-title":"Genes Dev"},{"key":"10.1016\/j.leukres.2011.10.022_bib0210","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.279.5351.707","article-title":"Phosphorylation and activation of p70s6k by PDK1","volume":"279","author":"Pullen","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.leukres.2011.10.022_bib0215","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/leu.2009.209","article-title":"Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia","volume":"24","author":"Jotta","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2011.10.022_bib0220","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/pbc.22414","article-title":"Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference","volume":"54","author":"Horton","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.leukres.2011.10.022_bib0225","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0140-6736(89)90417-0","article-title":"Rapamycin for immunosuppression in organ allografting","volume":"334","author":"Calne","year":"1989","journal-title":"Lancet"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611005200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611005200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T16:29:18Z","timestamp":1713198558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212611005200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0145212611005200"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2011.10.022","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}